CXCL9 and melanoma: Also, in another scientific study that analyzed plasma samples from 28 patients with advanced melanoma who were treated with pembrolizumab and nivolumab plus ipilimumab, responders (n = 18) had a greater quantity of CXCL9 and CXCL10 compared to non-responders (n = 10) [100].